CAH

News

Cardinal Health’s dependence on top customers leaves it ‘vulnerable’

Cardinal Health (NYSE:CAH) renewal of a key drug distribution contract with Walgreen Co. earlier this month brings renewed focus on just how heavily reliant Cardinal is on its top two customers. In Cardinal's fiscal 2010, Walgreen (24 percent) and CVS (22 percent) combined for a 46 percent share of revenues. That's up from a combined 43 percent in 2008. Adam Fein, a pharmaceutical industry consultant with Pembroke Consulting, stated on his blog Drug Channels: "The data show a company that's increasingly at the mercy of its two dominant customers."

By Brandon Glenn
News

Cardinal Health gets regulatory clearance for $1.3B Kinray buy

The Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The law generally requires a 30-day waiting period for a merger or acquisition to close so regulators have enough time to investigate the deal. Cardinal announced the deal last month, noting that adding Kinray would help expand its presence in the lucrative New York market.

By Brandon Glenn
presented by
Pharma

Eli Lilly to pay up to $800M for Alzheimer’s tracing agent maker

Indianapolis drug maker Eli Lilly & Co. (NYSE:LLY) has agreed to pay up to $800 million for Avid Radiopharmaceuticals, the Philadelphia developer of a tracing agent that can help diagnose Alzheimer's disease. The tracing agent, florbetapir F 18 -- which last week topped the Cleveland Clinic's Top 10 Medical Innovations list for 2011 -- is coupled with a PET scan to allow doctors to see inside patients' brains to detect beta-amyloid plaques, the tell-tale signature of Alzheimer's.

By Mary Vanac
sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab
Pharma

Cardinal Health expands ability to make molecular imaging agents

Cardinal Health Inc. (NYSE: CAH) will manage and operate the Knoxville, Tennessee, cyclotron facility of ProVision Healthcare through an agreement that expands the Dublin, Ohio, drug distributor's ability to make molecular imaging agents nationwide. Ohio's largest corporation has been partnering with academia and industry to push the boundaries of nuclear medicine -- and have first dibs on commercializing the industry's innovations -- by using its know-how and technologies to enable researchers to come up with new products.

By Mary Vanac